(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 10.6% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.7%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Charles River Laboratories International's revenue in 2023 is $3,781,267,000.On average, 6 Wall Street analysts forecast CRL's revenue for 2023 to be $216,168,349,262, with the lowest CRL revenue forecast at $211,184,581,392, and the highest CRL revenue forecast at $220,575,967,231. On average, 5 Wall Street analysts forecast CRL's revenue for 2024 to be $239,477,845,843, with the lowest CRL revenue forecast at $234,472,251,030, and the highest CRL revenue forecast at $243,991,545,810.
In 2025, CRL is forecast to generate $257,710,059,585 in revenue, with the lowest revenue forecast at $257,710,059,585 and the highest revenue forecast at $257,710,059,585.